~~<i id='25AFB05B23'><strike id='25AFB05B23'><tt id='25AFB05B23'><pre id='25AFB05B23'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

leisure time

author：entertainment 2025-09-04 22:02:00 - browse：68

MADRID — Merck is paying billions of dollars to partner with Daiichi Sankyo on a series of cancer drugs, underscoring the excitement around targeted chemotherapy treatments.

The deal includes a $4 billion upfront payment and an additional $1.5 billion over the next two years. Up to $16.5 billion more is on the table depending on the success of the drugs in development.

The announcement on Thursday night in the United States came on the eve of one the cancer field’s biggest annual conferences, the European Society for Medical Oncology Congress, being held this year in Madrid.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： UCB departs biotech trade group BIO

Wikipedia

explore

focus

hotspot

focus

ApatientwithcrutcheswalkpasttheskeletonofahospitaldestroyedbyaRussianattack.EvgeniyMaloletka/APInrec

WSS

U.K. sequencing study surfaces new findings about tumor DNA

A single drug, study failures leave Anavex with nothing but cash

Biden administration begins canceling student loan debt for 804,000 borrowers

GSK Flovent asthma inhalers replaced by authorized generics

The FDA must approve intranasal treatments for anaphylaxis

Bird flu researchers hone in on Finland’s mink farms

focus

leisure time

Wikipedia

The high cost of giving birth even with insurance

The biotech scorecard for Q1: 17 stock

BioMarin wins approval for gene therapy to treat hemophilia A

3 medical device trends to watch in 2024

Hollywood unions extend contract negotiations for actors

Biden administration begins canceling student loan debt for 804,000 borrowers

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

Jerome Adams on the need for new antivirals for Covid

How a scoliosis diagnosis changed the life of one young dancer

explore

Idaho college killings prosecutors challenge defense's grand jury claims

Treatments for cramps don't cut it. Why aren't there better options?

J&J to buy cancer drug developer Ambrx Biopharma

Feng Zhang CRISPR delivery startup lays off quarter of staff

Sweeping indictment could be Trump's biggest legal challenge yet: ANALYSIS

3 medical device trends to watch in 2024

focus

focus

hotspot

focus